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Heterozygous deletion of chromosome 17p renders
prostate cancer vulnerable to inhibition of RNA
polymerase II
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Xiaoming He 11,12, Xinna Zhang3,4, Guang Ji 1 & Xiongbin Lu2,3,4
Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events
in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding the cat-
alytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion
region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a
focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective
dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates
POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA
synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC
in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor,
α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for
CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC
harboring heterozygous deletion of 17p.
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Prostate cancer is among the most common male malig-nancies and one major leading cause of cancer mortality inmen1,2. Since the discovery of androgen dependence in
prostate cancer, the backbone therapy for prostate cancer has
been to lower androgen levels by surgical castration or androgen-
deprivation therapy3. However, although many patients initially
respond to androgen deprivation therapy, nearly all the patients
relapse and eventually develop castration-resistant prostate can-
cer (CRPC)4. Over the past decade, it has become clear that the
androgen receptor (AR) plays a pivotal role in the development of
resistance to hormone therapies in both primary and recurrent
prostate cancer. New therapeutic approaches in advanced pros-
tate cancer have focused on the AR protein, which led to the
development of AR-targeting agents, abiraterone acetate and
enzalutamide5.
Despite the success of androgen deprivation and AR-blocking
therapies, the newly developed therapies also suffer a short
therapeutic durability due to acquired resistance4,6. Thus,
researchers are now searching for more therapeutic targets, one of
which is prostate-specific membrane antigen (PSMA). PSMA is
highly expressed on the surface of nearly all prostate cancer cells
but is present on only a few normal tissues, making it an excellent
target for drugs that selectively attack tumors7. Radioactive ele-
ment lutetium-177-labeled PSMA antibody has shown promise in
treating patients who are resistant to other drug therapies8–10.
While it is hard to directly target variant forms of AR or altera-
tions in the AR gene that promote castration resistance, a small
molecular inhibitor against ROR-γ, an upstream regulator of AR,
was proven to effectively shut down AR signaling11. In mouse
CRPC models, treatment with ROR-γ inhibitors led to substantial
and prolonged regression of tumors, and restored their sensitivity
to the treatment of enzalutamide. In-depth understanding of
prostate cancer invasion, metastasis and drug resistance will help
identify more therapeutic targets and lead to new treatment
options.
The whole-genome sequencing of cancer genomes and other
associated omics efforts have empowered our knowledge of
human cancer biology and pathogenesis. These efforts have
facilitated personalized medicine to find new genetic alterations
in the context of a specific cancer. Comprehensive analyses of key
genomic changes in prostate cancer will accelerate our progress in
developing more effective ways to diagnose, treat and prevent this
disease. Recent studies have identified recurrent somatic muta-
tions, copy number variations, and chromosomal rearrangements
in prostate cancer12,13. A number of frequent genomic changes
are shared by primary and metastatic prostate cancer, including
E26 transformation-specific (ETS) fusions, point mutations in
SPOP, FOXA1, and TP53, and copy number alterations involving
MYC, RB1, and PTEN, although these alterations are differentially
enriched at different stages of prostate cancer12,13. Interestingly,
aberrations of BRCA2, BRCA1, and ATM were observed at a
much higher frequency in CRPC, indicating the potential appli-
cation of PARP inhibitors in treating this subset of cancers. In a
phase II study of olaparib14, a PARP inhibitor, it was proven to
have high response rates in patients with metastatic CRPC car-
rying DNA repair defects. While certain prostate cancer altera-
tions or signatures have prognostic clinical significance, the
therapeutic approach targeting those genomic events has not yet
been developed.
It has been long known from cytogenetic and loss of hetero-
zygosity (LOH) studies that deletions on the 17p frequently occur
in many types of human cancer15–17. While TP53 loss may play a
dominant role in the tumor initiation or progression, it remains
unclear whether many genes in the deletion region impact
tumorigenesis beyond TP53 loss alone. A recent study showed
that loss of Eif5a and Alox15b in the mouse 11B3 (syntenic to
human 17p13.1) cooperates with Trp53 (mouse orthologue of
TP53) deletion to produce more aggressive disease in lymphoma
and leukemia18. In this study, we find that 63% of metastatic
prostate cancer harbors heterozygous deletion of a region that
spans up to 20 megabases of DNA at 17p. We demonstrate that
POLR2A is included in the 17p deletion region along with TP53
in a majority of prostate cancers. POLR2A is the catalytic subunit
of the RNAP2 complex that is solely in charge of mRNA synthesis
in cells. POLR2A and RNAP2 activity is specifically inhibited by
α-amanitin, a small molecule peptide produced by the death cap
mushroom (Amanita phalloides)19,20. Inhibition of POLR2A with
α-amanitin-based ADC selectively suppresses the proliferation,
survival and tumor growth of CRPC cells harboring this genomic
event. Using a CRISPR-Cas9 screen, we uncover that hetero-
zygous deletion of 17p confers a selective dependence on RBX1,
inhibition of which had a synergistic and robust suppression in
the growth of CRPC along with the treatment of α-amanitin-
conjugated anti-EpCAM antibodies.
Results
Heterozygous deletion of 17p is frequent in prostate cancer.
TP53, a well-documented tumor suppressor gene, is frequently
inactivated by mutation or deletion in a majority of human
tumors21. However, the mutation and homozygous deletion of
TP53 are relatively infrequent events in prostate cancer,
accounting for only 12% (59 out of 492) and 8% (37 out of 492)
of total cases, respectively. In contrast, approximately 26% (126
out of 492) of all prostate tumor samples harbor heterozygous
loss of TP53 (Fig. 1a). Our recent studies have shown that het-
erozygous deletion of TP53 in human colorectal cancer fre-
quently encompasses a neighboring essential gene POLR2A,
rendering cancer cells with heterozygous loss of TP53 susceptible
to further inhibition of POLR2A22,23. The comprehensive ana-
lysis of prostate cancer genomes revealed that the TP53 deletion
is often included in a large fragment deletion that spans over
almost the whole short arm of chromosome 17 (17p) (Fig. 1b).
The loss of 17p is frequently detected at relatively late stages of
colorectal cancer development24,25, which may contribute to or
even determine the transition from the early-stage to advanced-
stage cancer. Consistent with the findings in colorectal cancer,
analysis of The Cancer Genome Atlas (TCGA) prostate dataset
revealed that 17p loss is readily detectable in low-grade T1
tumors, but was significantly increased in the advanced T2-T4
tumors (Fig. 1c, d). Moreover, the loss of 17p rises up to 63% (95
out of 150) in metastatic prostate cancer, whereas TP53 mutation
and homozygous deletion account for only 39 and 6% respec-
tively (Fig. 1e, f). Collectively, these results indicate the 17p loss
may play an important role in prostate cancer progression and
metastasis.
RBX1 is an essential gene for 17ploss CRPC cells. In the 17p
deletion region, there are as many as 200 protein-coding genes
and noncoding RNA genes, as well as even more regulatory ele-
ments for transcriptional and epigenetic activities. To identify
genes for which loss of function would lead to selective killing of
17p-deficient cells, we performed a CRISPR-based genetic screen
in DU145 (a CRPC cell line) and its isogenic line that had been
genetically modified to delete one copy of 17p from WDR81 to
MAP2K3 with the size of ~19.6 megabases (Supplementary
Fig. 1a–d). The isogenic pair of 17ploss and 17pneutral DU145 cells
displayed similar proliferation rate, suggesting that single 17p is
sufficient to maintain cell viability and proliferation (Supple-
mentary Fig. 1e). A pool of lentiviral CRISPR single guide RNA
(sgRNA) library was engineered to express sgRNAs targeting
3733 genes whose protein products localize mainly in the nucleus
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Fig. 1 Chromosome 17p loss is a frequent genomic event in prostate cancer. a Genomic alterations of TP53 (point mutation, shallow deletion and deep
deletion) in a TCGA prostate cancer dataset (TCGA provisional, n= 492) determined by cBioportal. Due to the intra-tumor heterogeneity, one tumor
tissue may include tumor cells with homozygous deletion of TP53 or with mutant TP53, as shown in a few cases. b Integrated analysis of 17p deletion in 155
prostate cancer patient samples. Frequency plots of the copy number abnormalities indicate degree of copy number loss (red) or gain (blue).
Representative genes in 17p deletion region are shown. c, d Distribution of heterozygous deletion of 17p among tumor clinical (c) and pathological
(d) stages in the TCGA prostate cancer dataset (Fisher’s exact test). e, f Genomic alterations of 17p heterozygous deletion (e) and TP53 mutations (f) in
the TCGA metastatic prostate cancer dataset (SU2C/PCF 2015, n= 150) determined by cBioportal
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(10 sgRNAs per gene, 37,330 sgRNAs in total). We infected the
isogenic pair of DU145 cell lines with the pooled lentiviruses, and
then assessed the relative depletion of sgRNAs after 14 population
doublings in order to identify genes whose depletion significantly
affected the proliferation of the 17ploss cells versus the 17pneutral
cells in vitro (Fig. 2a). High correlations were achieved among
replicates (Fig. 2b). Based on differential sgRNA representation
with empirical analysis of digital gene expression data in R
(edgeR)26, we uncovered a total of 181 essential genes (false-
discovery rate (FDR) < 0.05) that are independent of 17p loss in
DU145 cells. In comparison with available databases27,28, our
screen recovered 93.4% of the known core essential genes (85 of
91) included in the library and discovered 96 essential genes
specific to DU145 cells, suggesting the reliability of our screen
(Fig. 2c and Supplementary Data 1). We next sought to identify
essential genes only in the context of 17ploss. To this end, the
criterion is that the FDR of the gene in the 17ploss cells should be
less than 0.05, but be more than 0.9 in the 17pneutral cells. Two
genes (RBX1 and GTF2H1) were identified to meet this criterion
(Fig. 2d).
17ploss CRPC cells are sensitive to RBX1 depletion. To validate
the context-dependent essentiality of RBX1 and GTF2H1, par-
ental and the 17ploss DU145 cell lines were transduced with
lentivirus co-expressing red fluorescence protein (RFP) and small
hairpin RNA (shRNA) against RBX1 or GTF2H1, and cell via-
bility was monitored by the RFP signal. When RBX1 was knocked
down, the RFP-positive cells were dramatically reduced in the
17ploss cells 14 days post lentiviral transduction, but not in the
parental 17pneutral cells (Fig. 3a, b and Supplementary Fig. 2a).
Depletion of GTF2H1 also showed preferable cell killing effect in
the 17ploss DU145 cells (Supplementary Fig. 2b-d). Recent studies
identified RBX1 as a potentially druggable target for cancer
therapeutics29,30. Therefore, we focused on RBX1 for further
investigation. To confirm the context-dependent essentiality of
RBX1, we generated stable cell lines expressing doxycycline
(Dox)-inducible RBX1 shRNA in a panel of 17pneutral (22Rv1 and
DU145) and 17ploss (PC3 and VCaP) cells. 22Rv1, DU145, and
PC3 are CRPC cell lines, while VCaP is not a CRPC line but
harbors 17p loss. Specifically, the expression of Dox-induced
RBX1 shRNA led to markedly reduced proliferation in 17ploss
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Fig. 2 CRISPR-Cas9 screen identifies RBX1 as an essential gene for 17ploss prostate cancer cells. a Schematic illustration of CRISPR screening procedure in
the isogenic pair of DU145 cells. b Box plots showing the distribution of sgRNA frequencies at different time points. c Overlapping of essential genes from
this screen and from the previous reports. d Frequency histograms of enriched or depleted sgRNAs. POLR2A and EIF6 are two representatives of common
essential genes. RBX1 and GTF2H1 are representatives of selective essential genes in the context of 17p loss
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cells, in comparison with that of the corresponding cells expres-
sing control shRNA (Fig. 3c–e). Despite significant knockdown of
RBX1, the 17pneutral cells (22Rv1 and DU145) continued to
proliferate, whereas the 17ploss cells (PC3 and VCaP) exhibited
severe apoptosis (Fig. 3f). These results were in agreement with
our genomic screen. This growth defect was rescued by intro-
duction of a shRNA-resistant RBX1 cDNA construct in the
17ploss PC3 and VCaP cells, indicating the on-target effect of the
shRNA (Fig. 3g, h). The results suggest that RBX1 is a selectively
essential factor in prostate cancer cells harboring 17p loss.
Depletion of RBX1 inhibits 17ploss CRPC tumor growth
in vivo. To investigate the effect of RBX1 inhibition in CRPC
tumors, we conducted xenograft tumor studies using parental or
isogenic 17ploss DU145 cells expressing Dox-inducible
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RBX1 shRNA. In these studies, subcutaneously implanted tumors
were allowed to grow before Dox treatment for ~7 days. In
accordance with our findings in vitro, administration of mice
with doxycycline food markedly decreased the growth of xeno-
graft tumors derived from the 17ploss DU145 cells (Fig. 4a, b).
Efficiency of RBX1 knockdown in vivo was confirmed by
immunohistochemistry (IHC) staining (Fig. 4c and Supplemen-
tary Fig. 3a). However, there was no substantial difference
between Dox-treated and -untreated tumors derived from the
parental DU145 cells (Fig. 4a, b). Examination of end-point
tumor burden in Dox-treated or -untreated groups (n= 5 per
group) demonstrated that depletion of RBX1 led to profound
decreases in tumor weight (68.5% reduction, p < 0.001, Fig. 4b) of
the 17ploss tumors, and correspondingly, these tumors had a
marked reduction in cell proliferation (as measured by Ki-67
levels) and a significant increase in cell apoptosis (as measured by
Fig. 3 Prostate cancer cells with 17p deletion are highly sensitive to RBX1 depletion. a, b Effect of RBX1 knockdown on the proliferation of the parental and
isogenic 17ploss DU145 cells, determined by direct competition assay. Cells expressing RFP and control nonspecific shRNA (shNT) or shRBX1 were sorted
and mixed with control RFP-negative cells (1:1) and the RFP-positive cells were quantified at passages 2, 4, and 6 (a). Representative cell survival measured
by staining with crystal violet was shown in b. c–e Cell growth curves, based on crystal violet staining, of human prostate cancer cell lines expressing Dox-
inducible shNT or RBX1-specific shRNA (shRBX1 #1, shRBX1 #2) (c). RBX1 knockdown efficiency and representative image were shown in d and
e, respectively. f Fraction of apoptotic cells in the 17pneutral (22Rv1 and DU145) and 17ploss (PC3 and VCaP) cells expressing Dox-induced RBX1 shRNA at
4 days post Dox treatment. g, h Cell survival measured by crystal violet staining (g) and protein expression levels (h) of RBX1 in PC3 and VCaP cells
expressing shRBX1, control or ectopic RBX1. Data are representative of three independent experiments and analyze by unpaired two-tailed t-test. Error bars
denote SD. **, p < 0.01; ***, p < 0.001
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Fig. 4 Depletion of RBX1 inhibits the growth of 17ploss CRPC tumors in vivo. a–c Tumor growth curves (a), gross tumor images and weights (b) of xenograft
tumors derived from subcutaneously implanted parental and isogenic 17ploss DU145 cells expressing Dox-inducible RBX1 shRNA (n= 3). c RBX1
expression, cell proliferation and apoptosis in the above xenograft tumors were quantified. Scale bar, 10 mm. d–f Tumor growth curves (d), representative
bioluminescent images (e), and gross tumor weights (f) of xenograft tumors derived from orthotopically implanted 22Rv1 and PC3 cells expressing Dox-
inducible RBX1 shRNA (n= 5). Data are analyze by unpaired two-tailed t-test and are presented as the mean ± SD. ns not significant; **, p < 0.01
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cleaved caspase-3 levels) (Fig. 4c and Supplementary Fig. 3a). We
next sought to assess sensitivity to RBX1 ablation in an orthotopic
tumor model using 22Rv1 cells (17pneutral) and PC3 cells
(17ploss). NOD/SCID mice were injected orthotopically with
22Rv1 or PC3 cells into the dorsal lobe of prostate in order to
establish prostate tumor models. In line with observations made
in the DU145 xenograft mouse model, Dox-induced knockdown
of RBX1 led to a robust reduction in the growth of the 17ploss
PC3 tumors (Fig. 4d–f and Supplementary Fig. 3b). However,
RBX1 depletion only had a modest effect on the growth of the
17pneutral 22Rv1 tumors, suggesting that targeting RBX1 confers
therapeutic selectivity on the 17ploss CRPC tumors.
RBX1 modifies POLR2A by the K63-linked ubiquitination.
RBX1 is an E3 ubiquitin ligase and a functional component of
multiple cullin-RING-based E3 ubiquitin ligase (CRL) complexes
that mediate the ubiquitination and subsequent proteasomal
degradation of target proteins31–33. To search for the direct
functional association of RBX1 with the genes located in the 17p
deletion region, we first performed mass spectrometry to analyze
the RBX1-containing protein complex. As expected, regular
components of CRLs were identified, including cullins (CUL1,
CUL2, and CUL3) and those proteins for substrate recognition
(SKP2, VHL). Interestingly, p53 and POLR2A were both identi-
fied as putative RBX1-interacting proteins (Supplementary Fig. 4a
and Supplementary Data 2). It was noted that the 17ploss DU145
cells contain an inactivating mutation of the TP53 gene on the
remaining allele34. Thus, it is unlikely that inhibition of RBX1
kills cells by modulating p53 level or activity. To examine the
functional connection between POLR2A and RBX1, we first
validated their physical interaction in the cell. Western blot
analysis identified POLR2A in the RBX1-associated immuno-
precipitate of the DU145 cell lysates (Fig. 5a). Reciprocal analysis
in which immunoprecipitated POLR2A-associated proteins were
probed for RBX1 as well as other members of CRL complexes also
confirmed the POLR2A-RBX1 interaction (Fig. 5a and Supple-
mentary Fig. 4b). We hypothesized that POLR2A may be the
ubiquitination substrate of RBX1-associated CRL complexes.
Indeed, overexpression of RBX1 significantly increased the ubi-
quitination level of POLR2A, while silencing RBX1 had the
opposite effect (Fig. 5b, c). There are seven lysine residues on
ubiquitin as potential points of ubiquitination, in which K48-
linked ubiquitination targets proteins for degradation, whereas
K63-linked ubiquitination does not affect the stability of protein
substrates, but often regulates their functions35–37. As we did not
detect any significant changes of POLR2A protein levels upon
RBX1 overexpression or downregulation (Supplementary Fig. 4c),
we postulated that the RBX1-mediated ubiquitin modification on
POLR2A may be non-K48-linked. Wildtype, K48R or K63R
mutant form of His-tagged ubiquitin was transfected into DU145
cells with Dox-inducible expression of RBX1 shRNA. Ubiquiti-
nated POLR2A was isolated by immobilized metal affinity chro-
matography and detected by anti-POLR2A antibody.
Ubiquitinated POLR2A levels were considerably decreased after
Dox treatment in the cells expressing wildtype or K48R ubiquitin,
but not in the cells expressing K63R ubiquitin, suggesting K63-
linked ubiquitination is the primary form for RBX1-associated
ubiquitination of POLR2A (Fig. 5d). Conversely, overexpression
of RBX1 significantly increased ubiquitinated POLR2A levels in
the presence of wildtype and K48R ubiquitin, but not K63R
ubiquitin (Fig. 5e). To further verify the K63-associated ubiqui-
tination activity of RBX1, we analyzed the ubiquitination of
POLR2A labeled with wildtype, K48-only or K63-only ubiquitin
(all other lysine residues are replaced with arginine residues
except for K48 or K63). K63-only ubiquitin modification on
POLR2A was markedly reduced by 90% upon RBX1 depletion, in
striking contrast to modest reduction of wildtype or K48-only
ubiquitin modified POLR2A (Fig. 5f). Conversely, ectopic
expression of RBX1 dramatically increased the level of K63-only
ubiquitin-modified POLR2A, but not the level of K48-only ubi-
quitin-modified POLR2A (Fig. 5g). Interestingly, depletion of the
substrate recognition subunit SKP2, but not VHL, could partially
phenocopy the effect of RBX1 knockdown on the K63-mediated
ubiquitination of POLR2A, while overexpression of SKP2 pro-
moted the K63-mediated ubiquitination of POLR2A (Supple-
mentary Fig. 4d). This prompted us to think that SKP2 might be
one of the substrate-recognizing subunits for the ubiquitination of
POLR2A. To prove it, we performed in vitro pull-down experi-
ments. We observed that purified GST-SKP2 was able to pull
down a considerable amount of POLR2A compared to the well-
documented POLR2A interaction protein POLR2H38, indicating
the direct interaction of SKP2 with POLR2A (Supplementary
Fig. 4e). Moreover, by single plane confocal microscopy, we found
both SKP2 and RBX1 show significantly positive colocalization
with POLR2A (Supplementary Fig. 4f). Consistently, SKP2
knockdown partially mimicked the RBX1’s knockdown effect on
the 17ploss cell proliferation (Supplementary Fig. 4g). The weaker
effect of SKP2, compared to that of RBX1, suggest that POLR2A
may indeed interact with other CRL E3 ligases in addition to
SKP2.
RBX1 activates the POLR2A-dependent RNA transcription. As
the catalytic subunit of RNAP2, POLR2A is indispensable for
mRNA synthesis. We asked whether RBX1 modulates the activity
of RNAP2 via K63-linked ubiquitination of POLR2A. An isogenic
pair of DU145 cells were incubated with 5-Ethynyl uridine (EU),
a nucleotide analog for uridine, which is incorporated into nas-
cent mRNA during active RNA synthesis. EU contains an alkyne
that can react with an azide-containing fluorescent dye for
monitoring mRNA synthesis temporally and spatially39. We
found that RBX1 knockdown, indicated by red fluorescence
protein (RFP) levels co-expressed with RBX1 shRNAs, impaired
the global transcription in both 17ploss cells and 17pneutral cells
(Fig. 6a and Supplementary Fig. 5a). As expected, the global
transcription is associated with the levels of K63-linked, but not
K48-linked ubiquitination of POLR2A (Fig. 6b and Supplemen-
tary Fig. 5b). However, RBX1 depletion had more dramatic effect
in the 17ploss cells with ~75% of suppression on total RNA
synthesis, in comparison with ~25% of suppression in the
17pneutral cells (Fig. 6a). This is probably due to the abundant
expression of POLR2A in the cell, which serves as a reservoir to
maintain essential cell activities during proliferation. Specifically,
in contrast to parental cells, RBX1 depletion in the 17loss cells
resulted in much more inhibitory effects on the expression of
those short-lived mRNAs40 transcribed from genes such as FOS,
E2F3, and SNAI1, compared to the control 5s rRNA levels (Fig. 6c
and Supplementary Fig. 5c). Moreover, we used an in vitro
RNAP2-dependent run off assay to measure the de novo tran-
scription in vitro41. The HeLaScribe DNA template was incubated
with nuclear extracts from the isogenic DU145 cells expressing
Dox-inducible RBX1 shRNAs, and a transcription reaction
without nucleoside triphosphates served as a negative control.
The newly synthesized RNA was purified and quantified. Without
Dox-induced RBX1 depletion, 17ploss cells had a relatively modest
reduction on their mRNA transcriptional activity in comparison
with the parental cells (Fig. 6d), suggesting that heterozygous 17p
loss does not significantly impact cell activities, as observed in
many cancer cells with this genomic event. However, further
depletion of RBX1 in the 17loss cells resulted in much more severe
effects on the mRNA transcription (Fig. 6d).
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RBX1 depletion-sensitized 17ploss CRPC to POLR2A inhibi-
tion. Our recent studies have shown that collateral deletion of
POLR2A with TP53 in human colorectal cancer renders them
susceptible to further inhibition of POLR2A22. Similarly, as
observed in colorectal cancer, the POLR2A gene is almost always
co-deleted with TP53 in the 17p deletion region in prostate
cancer, and the expression levels of POLR2A, but not TP53, are
significantly correlated with the loss of 17p (Supplementary
Fig. 6a, b). In addition, this tight correlation between POLR2A
copy numbers and protein levels were further validated in a panel
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of human prostate cancer cell lines as well as a human tumor
tissue microarray including 169 prostate tumor samples (Fig. 7a
and Supplementary Fig. 6c, d). In comparison with the 17pneutral
cells (22Rv1, DU145), treatment of α-amanitin, a specific inhi-
bitor of POLR2A, had markedly higher levels of cell-killing effect
on the 17ploss cells (PC-3, VCaP). The half-maximum inhibitory
concentration (IC50) was ~0.3 µg ml−1 for the 17ploss cells, which
was 5–10 fold lower than that of the 17pneutral cells (Fig. 7b and
Supplementary Table 1). By contrast, 17ploss cells did not show
any greater sensitivity to the treatment of actinomycin D, a
nonspecific transcription inhibitor42 (Fig. 7c). The results suggest
that inhibiting POLR2A by α-amanitin specifically kills the
prostate cancer cells harboring 17p loss.
As the 17ploss cancer cells are vulnerable to the inhibition of
RBX1, we asked whether RBX1 inhibition can further improve
the efficacy of α-amanitin-based drug through combined action
in treating CRPC with 17p loss. To test it, the isogenic pair of
17pneutral and 17ploss DU145 cell lines expressing Dox-inducible
RBX1 shRNAs were treated simultaneously with Dox and α-
amanitin at a variety of combined doses (Fig. 7d, e). Dox-induced
inhibition of RBX1 exerted significantly enhanced cytotoxicity in
the 17ploss DU145 cells, but only had relatively modest effect on
their parental DU145 cells without 17p loss. A combination of
0.1 µg ml−1 of α-amanitin and Dox caused massive cell death
(over 80%) in the 17ploss cells. By contrast, the same combined
treatment only had a modest effect on the survival of the
17pneutral cells. As a control, α-amanitin alone only killed 50% of
17ploss cells at the concentration of 1.0 µg ml−1 (Fig. 7d, e).
Similarly, the 17ploss cells (PC3 and VCaP), upon Dox-induced
depletion of RBX1, were more sensitive to α-amanitin treatment,
showing a synergistic effect with a combination index (CI) <0.5
(Fig. 7f). The results clearly demonstrated that inhibition of RBX1
markedly reduced the effective dose of α-amanitin and achieved
better cell killing effect in the 17ploss cancer cells.
RBX1 inhibition potentiates the efficacy of α-amanitin ADC.
Based on the synergy of RBX1 depletion and α-amanitin-
mediated inhibition, we investigated the efficacy of the com-
bined treatment in 17ploss CRPC in vivo. The 17ploss DU145 cells
expressing Dox-inducible RBX1 were orthotopically implanted
into the prostate of NOD/SCID mice. Once tumors had been
established for 10 days post implantation, the tumor-bearing mice
were randomized and administrated with Dox food and α-
amanitin-conjugated anti-EpCAM antibodies43 (ADC, weekly,
twice in total) (Fig. 8a and Supplementary Fig. 7). Similar to our
previous data from colorectal cancer models22, the treatment of
ADC alone inhibited ~84% of tumor growth at the dose of 10 µg
kg−1 (corresponding to the amount of α-amanitin in the ADC).
Dox-induced depletion of RBX1 alone also exerted notable
inhibition on the tumor growth. However, combinatorial treat-
ment of ADC (3.0 or 1.0 µg kg−1) and Dox profoundly intensified
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the suppression of tumor growth, leading to nearly complete
(>90% reduction) tumor regression (8/8 or 6/8 mice, respec-
tively). Even combined with a low dose of ADC (0.3 µg kg−1),
RBX1 depletion had comparable effects to that of the treatment
with 3.0 µg kg−1 of ADC alone (Fig. 8b, c). IHC analyses con-
firmed that the combined treatment inhibited the tumor cell
proliferation and promoted their apoptosis, to a much greater
extent than the single agent ADC or Dox (Fig. 8d and Supple-
mentary Fig. 8a, b). The combinatorial treatment had no notable
toxicity in vivo as reflected by negligible changes of body weights
or blood liver enzymes (Supplementary Fig. 8c, d). Collectively,
these results suggested that heterozygous loss of 17p confers
therapeutic vulnerability of human CRPC to the inhibition of
POLR2A (on the 17p) and RBX1 (not on the 17P), and that
inhibiting RBX1 significantly sensitizes the CRPC to the treat-
ment of α-amanitin-antibody conjugates.
Discussion
The common treatment option for prostate cancer is to deprive
the levels of androgen by surgical castration or androgen-
deprivation therapy2,4–6. Hormone therapy is usually continued
in patients with metastatic prostate cancer. However, nearly all
the patients with metastatic prostate cancer eventually develop
CRPC. Therapeutic options for CRPC are often limited to che-
motherapy with the drugs such as docetaxel and cabazitaxel2,4–6.
The large-scale and multi-dimensional analyses of human pros-
tate cancer genomics now provide comprehensive profiles of the
cancer genomic alterations, which enables the development of
therapies that target these changes as well as prognosis that
identifies patients who may benefit from these therapies13.
Identifying tumor vulnerabilities of CRPC would provide novel
therapeutic approaches for this incurable disease. Similar to other
types of cancer, the tumor suppressor TP53 gene is also frequently
inactivated by mutation or deletion in human prostate cancer.
One of the major efforts in cancer therapeutics is to restore p53
activity in cancer cells. Different strategies have been taken to
develop small molecule compounds that specifically target mutant
p53 or p53 inhibitors such as Mdm2 and Mdmx44,45. However,
no effective p53-based therapy has been successfully translated
from bench to bedside due to the complexity of p53 signaling.
Therefore, identification of vulnerabilities conferred by TP53
deletion or mutation is a major challenge to target p53 aberrancy
in human cancers including CRPC.
Our recent study demonstrated that genomic deletion of TP53
frequently encompasses a neighboring essential gene, POLR2A,
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rendering cancer cells with heterozygous TP53 deletion vulner-
able to further suppression of POLR2A22. Of note, the TP53-
containing deletion often span over 20 megabases on the 17p and
more than 200 genes are co-deleted, which may impact prostate
tumor progression and metastasis. While it is impractical to
delineate individual gene contribution and their interactions in
tumorigenesis, we reasoned that the 17p loss may create ther-
apeutic vulnerabilities as some of the genes are in charge of
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essential cellular activities, as observed for POLR2A. A number of
studies have shown that CRISPR-based screens are a systematic
approach to identify essential genes required for cell survival and
proliferation46–48. Although a majority of the essential genes are
shared between different cancer cell types, some of them are
essential only in the context of specific genomic profiles, sug-
gesting that essentiality is not an intrinsic property of a gene but
is rather impacted by genetic and environmental factors. As an
example, analysis of differentially essential genes between Ras-
dependent and -independent cell lines uncovered PREX1 as an
acute myeloid leukemia-specific activator of the oncogenic Ras-
MAPK signaling49. On this basis, we proposed that prostate
cancer cells with 17p loss would have their specific gene depen-
dency compared to their counterparts without 17p loss. In this
study, RBX1 stands out as an essential gene associated with 17p
loss in CRPC cells.
As a key catalytic subunit of RNAP2, POLR2A contains a
carboxyl terminal domain (CTD) composed of 52 heptapeptide
repeats (YSPTSPS) that are essential for the RNA polymerase
activity50. Phosphorylation of the heptapeptide repeats regulates
the activity of POLR2A. The phosphorylation state is believed to
result from the balanced action of CTD kinases (CDK7 and
CDK9) and the Ser/Thr phosphatase CTDSP1. We found that the
E3 ubiquitin ligase RBX1 is a new direct interactor of POLR2A.
RBX1 promotes the enzymatic activity of POLR2A via K63-linked
poly-ubiquitination. In support of its functional essentiality,
RBX1 expression levels are inversely correlated with POLR2A in
human prostate cancers (r=−0.45, TCGA), suggesting that loss
of POLR2A in the 17ploss cells is probably compensated by the
upregulated expression of RBX1 in prostate tumors. Inhibition of
RBX1 markedly enhanced the effectivity of α-amanitin-
conjugated ADC in treating CRPC in vivo, indicating the trans-
lational potential of the RBX1-targeted therapeutic approach.
Results of CRISPR-based knockout (Fig. 2) or silencing of
RBX1 (Figs. 3 and 4) in CRPC cell lines revealed that RBX1 is
essential for proliferation only in 17ploss cells, but not in 17pneutral
cells. These findings suggest that RBX1 is not an essential gene for
proliferation at least in DU145 cells. However, RBX1 was pre-
viously shown to be an essential gene required for mouse
embryonic development51. In addition, CRISPR-based genome-
wide analysis showed that RBX1 is an essential gene for those four
cell lines tested (KBM7, K562, Jiyoye, and Raji)52,53. To under-
stand this discrepancy, we have analyzed RBX1 genetic integrity
in a large set of tumor cells using Cancer Cell Line Encyclopedia
(CCLE) database. The results revealed homozygous deletion of
RBX1 in at least 11 cell lines, including ACHN, HT115, KALS-1,
LCLC-103H, MSTO-211H, REC-1, SH-SY5Y, SK-CO-1, SK-N-
SH, SNU-719, and TE-1. Moreover, KBM7 is a haploid cell line
that only contains one copy of Chr17, while K562 is a cell line
with heterozygous loss of 17p. Of note, the genomic data of Jiyoye
is unavailable from CCLE, whereas Raji cells seem to contain
neural copy number of 17p. Collectively these data suggest that
the essentiality of RBX1 for cell growth may be context-
dependent. Given our work on DU145 and the CCLE analysis
of 11 tumor cell lines, it appears that RBX1 is not essential for
global cell survival in a significant set of tumor cell lines. More-
over, our study has raised possibility that hemizygosity may be a
significant factor that sensitizes RBX1’s essentiality. Results from
CRISPR experiments with the haploid KBM7 and the17p-
deficient K562 cells from the Wang study appear in line with
our assertion. Finally, both RBX1 and its paralog RBX2 (also
named as RNF7), which shares 7 out of 8 Cys/His residues that
constitute their RING finger domain, are found to be evolutio-
narily conserved among many species from yeast to humans54.
More importantly, either human RBX1 or RBX2 can rescue the
lethal phenotype caused by deletion of the RBX ortholog Hrt1 in
yeast, indicating they are functionally redundant to some
extent29.
Beside the recent approval of Kadcyla (T-DM1) and Adcetris
(SGN-35), a number of ADCs have entered clinical trials55–57.
However, most ADCs are based on a few toxic compounds, such as
auristatins and maytansines, and their mechanisms of action are
often limited to the microtubule disruption. The clinical efficacy of
these ADCs could suffer from limited activity in different cancer
indications and in resistant cancer cells. Accordingly, the use of new
drugs that function via alternative toxicity mechanisms will poten-
tially enhance the therapeutic activity of ADCs. As one of the newly
developed warheads in ADCs, α-amanitin has advantages over other
commonly used toxins because of its unique mode of action and
molecular characteristics22,43. In particular, as the most potent inhi-
bitor of cellular transcription, α-amanitin targets the unique vulner-
ability of cancer cells conferred by genomic loss of POLR2A and 17p,
which significantly increases therapeutic index by selectively killing
cancer cells with this genomic aberrancy, and accordingly reduces
potential in vivo toxicity. Inhibition of RNAP2 by α-amanitin leads
not only to apoptosis of dividing cells, but also to that of slowly
growing cells, as often observed in metastatic prostate cancer.
Therapeutic strategy using RBX1 inhibitors in combination with the
α-amanitin-conjugated ADCs will integrate cancer genomics into
precision medicine to fuel exciting progress against a challenging
class of human cancers. Heterozygous loss of TP53 and 17p is also
found in other types of cancer, suggesting that α-amanitin-based
ADCs may be great drug candidates in those cancers. In the past
decade, the ubiquitin–proteasome system has emerged as an attrac-
tive target for the development of novel therapeutics58,59. E3 ubi-
quitin ligases are particularly valuable targets because they confer
substrate specificity on the ubiquitin system. RBX1 is a key compo-
nent that binds and ubiquitinates substrate proteins in CRL com-
plexes. Further structural investigation of the RBX1-containing CRLs
will allow us to better understand the assembly and structure of CRL
complexes, and empower the design of small-molecule inhibitors and
modulators of CRL activity.
Methods
Tissue culture and tissue microarray. HEK293T, 22Rv1, DU145, MDA PCa 2b,
NCI H660, PC3, LNCaP, VCaP, MEG01, KU812, and K562 cell lines were pur-
chased from the American Type Culture Collection (ATCC). KBM7 cell lines was
ordered from Horizon Discovery. All cell lines were maintained under standard
conditions specified by the manufacturer and were tested negative for mycoplasma
contamination using the Mycoplasma detection kit (Lonza). Prostate tumor tissue
microarray (PR8011bt, PR1921a, PR632) were purchased from Biomax, including
228 prostate tumor samples and 51 normal prostate tissue samples.
Antibodies. Anti-RBX1 antibody (ab133565, 1:1000 dilution for immunoblotting
and 1:100 for IHC) was purchased from Abcam. Anti-POLR2A antibody (sc-
47701,1:5000 dilution for immunoblotting and 1:200 for IHC), anti-CUL1 antibody
(sc-17775, 1:1000 dilution), anti-CUL2 antibody (sc-166506, 1:1000 dilution), anti-
CUL4A/4B antibody (sc-377188, 1:1000 dilution), anti-CUL5 antibody (sc-373822,
1:1000 dilution) and anti-CUL7 (sc-53810, 1:1000 dilution) antibody were obtained
from Santa Cruz. Anti-Ki67 antibody (#12075, 1:100 dilution), anti-cleaved Cas-
pase-3 (Asp175) (#9664, 1:1000 dilution), Anti-SKP2 antibody (#2652, 1:1000
dilution), Anti-VHL antibody (#68547, 1:1000 dilution) and Anti-CUL3 (#2759,
1:1000 dilution) were purchased from Cell Signaling Technology. Anti-p53 (sc-126,
1:1000 dilution), anti-actin (sc-1616, 1:5000 dilution), HRP-anti-mouse IgG (sc-
2055, 1:5000 dilution), HRP-mouse IgG kappa binding protein (sc-516102, 1:5000
dilution) and HRP-anti-rabbit IgG (sc-2054, 1:5000 dilution) were purchased from
Santa Cruz.
shRNA interference. Lentiviral pGIPZ vectors expressing non-silencing shRNA
control, shRBX1 and shGTF2H1 were purchased from Dharmacon (originally
from Open Biosystems). The hairpin sequence in the pGIPZ shRBX1 #1 were
cloned into the pTRIPZ (Dharmacon) using standard protocol provided by the
manufacturer. The TRIPZ vector is a Dox-inducible system with a red fluorescence
protein reporter. The shRNA clone identification numbers and shRNA sequences
are as below:
shRBX1 #1 (V3LHS_637677, 5′-GCATTAAAGCAGCGTATC-3′)
shRBX1 #2 (V3LHS_405194, 5′-GCATTAAAGCAGCGTATC-3′)
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shRBX1 #3 (V3LHS_337320, 5′-GCATTAAAGCAGCGTATC-3′)
shGTF2H1 #1 (V3LHS_399134, 5′-GCATTAAAGCAGCGTATC-3′)
shGTF2H1 #2 (V3LHS_399137, 5′-GCATTAAAGCAGCGTATC-3′)
shSKP2 #1 (V2LHS_199552, 5′-TATCACTTAAGTCTAGATG-3′)
shSKP2 #2 (V2LHS_12473, 5′-ATACTTCATAGACAACTGG-3′)
shVHL #1(V2LHS_202399, 5′-TAATGAATCTAAGTCTAGC-3′)
shVHL #2(V2LHS_262050, 5′-AATTCTCAGGCTTGACTAG-3′)
Generation of sgRNA-expressing vectors. Briefly, the vector DNA expressing
Cas9 and sgRNA was digested with BbsI and treated with alkaline phosphatase.
The linearized vector was then gel purified. Meanwhile, the pair of oligo DNA for
sgRNA targeting POLR2A was annealed and phosphorylated. The sequences of
oligo DNA are as follows: 5′-CAGCCGACTGAACAGCCGTA-3′ (WDR81) and
5′-GAGGCAGACTCACGTGGGGT-3′ (MAP2K3). The annealed sgRNA was
subsequently ligated to the linearized vector. Genome-editing efficacy was tested by
Suveyor assay60.
Immunoblotting. Cell extracts were prepared using cell lysis buffer (50 mM Tris,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, 1 mM sodium fluoride, 5 mM sodium vanadate, 1
μg ml−1 of aprotinin, leupeptin, and pepstatin). Proteins were resolved by SDS-
polyacrylamide gel electrophoresis gels and then proteins were transferred (Bio-
Rad) to polyvinylidene difluoride membranes (Millipore). After blocked with 5%
milk, membranes were incubated with indicated primary antibodies (1:1000 dilu-
tion). Subsequently, membranes were washed and incubated with peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology). Finally, the relevant
protein was visualized by enhanced chemiluminescence system (PerkinElmer)
according to the manufacturer’s instructions. Uncropped scans of the western blots
are presented in the Supplementary Fig. 9.
Immunoprecipitation. Cells were lysed on ice for 30 min in immunoprecipitation
buffer (1% NP-40, 50 mM Tris-HCl, 500 mM NaCl and 5 mM EDTA) containing
protease inhibitor cocktail. Protein concentration was determined by the BCA
assay (Thermos). Cell lysates (800 μg) were incubated with 2 μg of indicated
antibodies or control normal IgG at 4 °C overnight with rotary agitation. Protein A/
G-sepharose beads were then added to the lysates and incubated for another 4 h.
Beads were washed three times with ice-cold immunoprecipitation buffer and
boiled for 10 min in 1× sample loading buffer. Total cell lysates and immuno-
precipitates were resolved by SDS-polyacrylamide gel electrophoresis and analyzed
either by western blotting or stained with silver nitrate. Protein bands were excised
and subjected to mass spectrometry analysis at the MD Anderson Proteomics and
Metabolomics Core.
GST pull-down assay. Two micrograms of GST-POLR2H (LSBio, G29812), GST-
SKP2 (LSBio, G30419), or control GST protein (Sigma, SRP5348) was immobilized
on agarose beads (Glutathione Sepharose 4B) and incubated with 200 µg of lysates
from DU145 cells at 4 °C for 2 h. Bound protein was washed five times with NETN
buffer (1% NP-40, 50 mM Tris-HCl, 500 mM NaCl and 5 mM EDTA) and was
subjected to SDS-PAGE gel electrophoresis and detected by using anti-POLR2A
antibody.
Immunohistochemistry. Briefly, samples were deparaffinized and rehydrated
followed by antigen retrieving used 0.01 M sodium-citrate buffer (pH 6.0) at a sub-
boiling temperature for 10 min. The sections were then incubated with 3%
hydrogen peroxide for 10 min to block endogenous peroxidase activity. After 1 h of
pre-incubation in 5% normal goat serum, the samples were incubated with indi-
cated primary antibodies at 4 °C overnight. The sections were then washed three
times and incubated with secondary antibodies. Counterstaining color was carried
out using Harris modified haematoxylin. All immunostained slides were scanned
on the Automate Cellular Image System III for quantification by digital image
analysis.
Immunofluorescence. Cells grown on coverslips were fixed in 3% paraformalde-
hyde in phosphate-buffered saline (PBS) at room temperature for 20 min. After
fixation, cells were subjected to 0.5% Triton X-100 for 10 min and then blocked
with 5% goat serum in PBS for 1 h at room temperature. Coverslips were immu-
nostained with indicated primary antibodies in 5% goat serum in wet chamber at 4
°C overnight. Coverslips were then washed and incubated with secondary anti-
bodies (Alexa Fluror 594 and Alexa fluror 488) for 1 h at room temperature. Cells
were then stained with DAPI to visualize nuclear DNA. The coverslips were
mounted onto glass slides with anti-fade solution. Single plane confocal images
were acquired with Olympus FV-1000 MPE system (Center Valley, PA). Coloca-
lization analysis was performed with the use of IMARIS software colocalization
module (Bitplane, Concord, MA).
Genomic DNA isolation and copy number validation. Total genomic DNA was
extracted either from cell lines using DNeasy Blood & Tissue Kit (Qiagen) or from
human tissue specimen using QIAamp DNA FFPE Tissue Kit (Qiagen) according
to the manufacturer’s instructions. The copy number variations for PSMB6, TP53,
POLR2A, and FLCN were determined using TaqMan probes and TaqMan PCR kit.
The reference gene TERT was quantified in the same reaction at the same time for
each DNA sample.
RNA isolation and quantitative PCR. Total RNA were isolated using RNeasy
Micro kit (Qiagen) and then reverse-transcribed using iScript cDNA Synthesis Kit
(Bio-Rad). The resulting cDNA was used for qPCR using iTaq Universal SYBR
Green Supermix (Bio-Rad) with specific primers for each gene and the results were
normalized to 18 S rRNA control. The primer sequences are:
RBX1: 5′-TTGTGGTTGATAACTGTGCCAT-3′; 5′-GACGCCTGGTTAGCT
TGACAT-3′; GTF2H1: 5′-GACCTTGTTGTGAGTCAAGTGA-3′; 5′-CCTGCTT
ATGATTGGATGTGGAA-3′; FOS: 5′-CCGGGGATAGCCTCTCTTACT-3′; 5′-C
CAGGTCCGTGCAGAAGTC-3′;
E2F3: 5′-AGAAAGCGGTCATCAGTACCT-3′; 5′-TGGACTTCGTAGTGCAG
CTCT-3′;
SNAIL1: 5′-TCGGAAGCCTAACTACAGCGA-3′; 5′-AGATGAGCATTGGC
AGCGAG-3′;
5S rRNA: 5′-GGCCATACCACCCTGAACGC-3′; 5′-CAGCACCCGGTATTC
CCAGG-3′;
18S rRNA: 5′-TGTGCCGCTAGAGGTGAAATT-3′; 5′-TGGCAAATGCTTTC
GCTTT-3′.
Cell survival assay. Equal numbers of cells were plated in 12-well plates in tri-
plicate. After 24 h cells were treated with α-amanitin or actinomycin D at indicated
concentrations for another 72 h. Cells were then fixed with 10% methanol and
stained with 0.1% crystal violet (dissolved in 10% methanol). After staining, wells
were washed three times and destained with acetic acid. The absorbance of the
crystal violet solution was measured at 590 nm.
Focused CRISPR-Cas9 genetic screening. The CRISPR-Cas9 screen was per-
formed using the Human CRISPR enriched pooled library for nuclear proteins
(Addgene # 51047), which contains 37,330 guides and an average of 10 guides per
gene46,47,61. Briefly, isogenic parental or 17ploss DU145 cells were transduced with
Dox-inducible FLAG-Cas9 vector. A single colony with robust Cas9 expression
(>50-fold induction) upon doxycycline treatment was selected for genetic screen-
ing. A total of 90 million DU145 cells were transduced with viral supernatant at
MOI of 0.3 and selected with blasticidin for 24 h after infection for 3 days. Ten
million cells were harvested for genomic DNA extraction 24 h after infection. The
remaining cells were cultured in medium containing 1 µg ml−1 doxycycline for 14
doublings before being harvested for genomic DNA extraction. Nested PCR was
performed on genomic DNA to extract sgRNAs information and subjected to
HiSeq 2500 (Illumina) with a single-end 50 bp run. Data were analyzed by edgeR.
The following nested PCR primers are used:
Outer Primer 1: 5′-GCCGGCTCGAGTGTACAAAA-3′
Outer Primer 2: 5′-AGCGCTAGCTAATGCCAACTT-3′
Inner Primer 1:
5′-CAAGCAGAAGACGGCATACGAGATCXXXXXTTTCTTGGGTAGT
TTGCAGTTTT-3′
(XXXXX denotes the sample barcode)
Inner Primer 2:
5′-AATGATACGGCGACCACCGAGATCTACACCGACTCGGTGCCACT
TTT-3′
Illumina Sequencing primer:
5′-
CGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGC
TATTTCTAG
-CTCTAAAAC-3′
Indexing primer:
5′-TTTCAAGTTACGGTAAGCATATGATAGTCCATTTTAAAACATAA
TTTTAAAACTGCAAA
-CTACCCAAGAAA-3′.
Differential representation analysis. The bioinformatics analysis was modified
from a recent report26. Briefly, counts for each sgRNA was first normalized using
the following method for visualization:
d ¼ log2 count ´ 10
6
total reads
þ 1
 
The representation analysis was then conducted with Bioconductor edgeR package
(v3.18.1) in statistical programming environment R (v3.4.1), and the exact statis-
tical method was carried out to detect over/under-represented individual sgRNAs
between 17ploss and 17pneutral groups, and FDR < 0.05 was considered as statisti-
cally significant, while FDR > 0.9 was considered no differences between two
conditions (day 0 and day 14). Subsequently, the camera gene-set test was used to
prioritize genes based on ranking of sgRNAs that target the same gene.
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Apoptosis analysis. 22Rv1, DU145, PC3, and VCaP cell lines were treated with 1
µg ml−1 doxycycline for 4 days and stained with annexin V-PE and 7-AAD
(Biovision). Apoptosis was then analyzed by flow cytometry according to the
manufacturer’s instructions. Live cells (annexin V-negative, 7-AAD-negative), pre-
apoptotic (annexin V-positive, 7-AAD-negative) and apoptotic cells (annexin V-
positive, 7-AAD-positive) were included in the analysis.
Amnis ImageStreamX. The internalization of HEA125 (EpCAM) and Ama-
HEA125 was assessed using imagestream flow cytometry. Briefly, 2.5 × 106 WI-38
and DU145 (parental or 17ploss) cells were incubated with indicated antibody or
ADC for 30 min at 4 °C in the dark. After washing twice with 1% BSA in PBS
containing 0.02% Azide, the cells were stained with the secondary anti-Human IgG
antibody conjugated with alexa fluor 594 (Ref A11014, Life technologies) for 20
min at 4 °C in the dark. The cells were washed twice and kept at 4 °C or placed in
culture medium at 37 °C for 1 h. The cultured cells were washed again and all the
samples were resuspended and analyzed immediately on the AMNIS Imagestream
(Imagestream X Mark II Imaging cytometer, EMD Millipore). We acquired 10,000
cells for each condition. The cellular uptake was quantified using the Internaliza-
tion wizard of the IDEAS software.
Prostate tumor xenograft mouse model. Male NOD/SCID mice (4–6 weeks old)
were purchased from Jackson Laboratories. All studies were approved and super-
vised by the Institutional Animal Care and Use Committee of MD Anderson Cancer
Center and Indiana University. Dox-inducible parental or isogenic 17ploss DU145
cancer cells (1 × 106) in 100 μl PBS with 50% Matrigel (BD Biosciences) were
injected subcutaneously into the dorsal flank using a 100-μl Hamilton microliter
syringe. Once the tumors reached a palpable stage (~100 mm3), the animals were
randomized and treated with or without doxycycline food (200mg kg−1, Bio-Serv).
Growth in tumor volume was recorded using digital calipers and tumor volumes
were estimated using the formula 0.5 × L ×W2, where L is the longest diameter and
W is the shortest diameter. For orthotopic prostate tumor model, the NOD/SCID
mice were anaesthetized with 2% isoflurane (inhalation) and 22Rv1 and PC3 cells
(1 × 106) expressing luciferase were implanted into the dorsal prostate62. Ten days
after cell injection, mice bearing tumors were randomly divided into four groups
and treated with or without doxycycline food as mentioned above. To determine
whether RBX1 knockdown sensitizes prostate tumor cells to the treatment of ADC.
Isogenic 17ploss DU145 cells (1 × 106) cells stably expressing Dox-inducible
RBX1 shRNA were implanted into the dorsal prostate of the male NOD/SCID mice.
Ten days after cell injection, mice bearing tumors were randomly divided into eight
treatment groups: (1) free anti-EpCAM antibodies; (2) 10.0 µg kg−1 ADC; (3) 3.0 µg
kg−1 ADC; (4) 1.0 µg kg−1 ADC; (5) Dox+ free anti-EpCAM antibodies; (6) Dox
+ 3.0 µg kg−1 ADC; (7) Dox+ 1.0 µg kg−1 ADC; (8) Dox+ 0.3 µg kg−1 ADC.
Doxycycline food was administered to the indicated group from day 10 to day 36.
Tumor growth was monitored by the IVIS system after luciferin injection for 15
min. Loss of body weight during the course of the study was also monitored. At the
end of the studies mice were killed and tumors extracted, weighed and fixed in
formalin solution and processed for sectioning and immunohistochemistry staining.
In vitro transcription assay. In vitro transcription reactions were set up as
described above and the nuclear extraction was purified from DU145 cells using
Nuclear Extraction Kit (Abcam). The protein concentration of each sample was
determined by BCA Protein Assay Kit (Thermo). Briefly, equal amount of nuclear
extraction was mixed with the in vitro transcription buffer, linear DNA templates
either pEGFP-N1 or HeLaScribe Positive control DNA (HS DNA) following the
manufacturer’s recipe. A standard reaction containing no NTPs was used as a
“negative transcription control”. The resulting RNA was purified using RNeasy
Micro Kit (Qiagen) and BaselineZero DNase Kit (Epicenter), and was subjected to
reverse transcription using Sensiscript RT kit (Qiagen). After reaction, 1 µl of the
reverse transcription mix was used for either standard PCR amplification or qPCR
to visualize the quantity of the in vitro transcribed RNA product. The primers for
generating the linear DNA are:
HS-DNA:
5′-CTCATGTTTGACAGCTTATCGATCCGGGC-3′;
5′-ACAGGACGGGTGTGGTCGCCATGAT-3′.
The primer-Probe mix for detection of HSDNA transcript by qPCR are
Primers: 5′-GCCGGGCCTCTTGCGGGATAT-3′ and 5′-
CGGCCAAAGCGGTCGGACAGT-3′; Probe: 5′-FAM-
TGGCGTGCTGCTAGCGCTAT-BHQ3′;
In vivo ubiquitination assay. The ubiquitination assays were modified from a
previous study63. DU145 cells were transiently co-transfected with indicated
plasmids. Forty-eight hours after transfection cells were treated with 5 μg ml−1
MG132 (Sigma) for 12 h. Cells were then harvested and lysed in denaturing buffer
(6M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4 and 10 mM imidazole). The cell
lysates were incubated with nickel beads for 3 h, washed and immunoblotted with
indicated antibodies.
Transcription assay. Nascent RNA was labeled by 5-ethynyl uridine (5-EU)
incorporation and was evaluated by using the Click-iT RNA Imaging Kit
(Invitrogen)39. RBX1 or control shRNA expressed cells were indicated by tRFP
signal. 5-EU signal, RFP and DAPI staining were captured using the Leica imaging
system. Images were processed by CellProfiler Software. DAPI staining was used to
define the area of the nuclei, and the fluorescence signal intensity of 5-EU in every
tRFP expressed cells was quantified for each nucleus.
Statistical analysis. Each experiment was repeated twice or more, unless other-
wise noted. No samples or animals were excluded from the analysis. For the mouse
experiment, no statistical method was used to predetermine sample size. The
samples or animals were randomly assigned to different treatment groups. A
laboratory technician who provided animal care and collected data was blinded to
the group allocation during all animal experiments and outcome assessment.
Differences between two groups were analyzed by the Student’s t-test. One-way
ANOVA followed by Tukey’s t-test was conducted to compare three or more
groups of independent samples. A p value < 0.05 was considered statistically
significant.
Data availability
All relevant data are available from authors upon request.
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